新輔助放化療對cⅡ-cⅢ期中低位直腸癌的療效分析及對VEGF表達(dá)的影響
發(fā)布時(shí)間:2019-03-17 15:21
【摘要】:背景 近年來,許多學(xué)者開始對如何降低局部晚期直腸癌患者的局部復(fù)發(fā)率和改善預(yù)后生存情況進(jìn)行了多種模式的探索。隨著新輔助放化療(NCRT)在乳腺癌治療中的療效被肯定和直腸癌術(shù)后放化療取得的可靠效果,其逐漸被應(yīng)用于直腸癌,到現(xiàn)在已成為局部晚期直腸(LARC)癌多學(xué)科綜合治療的重要組成部分,得到了眾多醫(yī)療中心的認(rèn)同。NCCN指南及《中國結(jié)直腸癌診療規(guī)范》中也都明確指出:對于距肛門12cm以內(nèi)的cⅡ-c Ⅲ期直腸癌推薦行NCRT。但NCRT對LARC的預(yù)后生存影響仍存在爭議。本研究分兩部分,目的如下:1.分析NCRT對cⅡ-c Ⅲ期中低位直腸癌的治療療效;2.了解NCRT對血管內(nèi)皮生長因子(VEGF)的影響,分析其在預(yù)測NCRT敏感性上的作用。第一部分NCRT對cⅡ-cⅢ期中低位直腸癌的療效目的:探討NCRT對cⅡ-cⅢ期中低位直腸癌患者的臨床療效方法:回顧性分析了2008年1月—2011年12月期間在陜西省人民院住院治療的cⅡ-cⅢ期的154例中低位直腸癌患者。根據(jù)是否接受NCRT將患者分組,其中NCRT組(A組)62例,直接手術(shù)組(B組)92例。統(tǒng)計(jì)兩組患者的一般病理特征及手術(shù)相關(guān)資料。分析兩組患者在腫瘤保肛率、手術(shù)相關(guān)并發(fā)癥、術(shù)后腫瘤復(fù)發(fā)率及術(shù)后生存率上的差異。結(jié)果:A組患者在NCRT后有8.1%(5/62)達(dá)到完全緩解(CR),有48.4%(30/62)達(dá)到部分緩解(PR),有43.5%(27/62)達(dá)到穩(wěn)定(SD),無疾病進(jìn)展病例;A組保肛率為66.7%(24/36),高于B組的36.7%(18/49),差異有統(tǒng)計(jì)學(xué)意義(P0.05);兩組在術(shù)中出血量、腸梗阻及吻合口瘺等發(fā)生率上的差異無統(tǒng)計(jì)學(xué)意義(均P0.05);但A組患者術(shù)后切口愈合不良及前切除綜合征的的發(fā)生率較B組高,差異有統(tǒng)計(jì)學(xué)意義(均P0.05)。分析隨訪資料后發(fā)現(xiàn):兩組的5年總生存率(OS)無差別,但A組的5年無瘤生存率(DFS)較B組高(P=0.007)。結(jié)論:1.NCRT能使cⅡ-c Ⅲ期中低位直腸癌縮小、降期,能降低術(shù)后局部復(fù)發(fā)率,還能提高保肛率;2.NCRT不能改善cⅡ-c Ⅲ期中低位直腸癌患者術(shù)后5年的OS,但可以提高術(shù)后5年的DFS第二部分NCRT對直腸癌組織VEGF表達(dá)的影響目的:1.NCRT對直腸癌組織VEGF表達(dá)的影響;2.探討VEGF在預(yù)測NCRT敏感性上的作用。方法:收集62例NCRT前及NCRT后的直腸癌患者的組織病理標(biāo)本切片,分別標(biāo)記為NCRT前組及NCRT后組,并以同期15例直接手術(shù)的直腸癌患者的癌旁5cm且經(jīng)病理證實(shí)為正常的直腸組織為對照組,通過免疫組織化學(xué)法分別檢測VEGF在NCRT前組、NCRT后組及對照組中的表達(dá),比較NCRT前組與對照組、NCRT前組、NCRT后組間的表達(dá)差異。根據(jù)新輔助治療反應(yīng)分級系統(tǒng)判斷腫瘤對NCRT的敏感性,探討VEGF表達(dá)與NCRT敏感性的關(guān)系。結(jié)果:VEGF在對照組中陽性率為26.7%(4/15),在NCRT前組中陽性率為77.4%(48/62),在NCRT后組中陽性率為41.9%(26/62)。VEGF的陽性表達(dá)率在對照組與NCRT前組相比,差異有統(tǒng)計(jì)學(xué)意義(x2=14.189,P0.001);在NCRT前組與NCRT后組相比較,VEGF的陽性表達(dá)率差異也有統(tǒng)計(jì)學(xué)意義(x2=16.221,P0.001)。根據(jù)術(shù)后病理采用改良自Ryan等的新輔助治療反應(yīng)分級系統(tǒng)判定有44例患者對NCRT敏感,在對NCRT敏感的患者中,接受NCRT前VEGF陽性表達(dá)者約88.6%(39/44);在對NCRT不敏感的患者中,VEGF陽性者約50%(9/18),通過對NCRT前VEGF表達(dá)情況與NCRT敏感性的相關(guān)性研究顯示,NCRT敏感性與VEGF的表達(dá)成等級相關(guān)(r=0.483,P=0.000)。結(jié)論:1.NCRT能夠降顯著低直腸癌組織中VEGF的表達(dá);2.VEGF表達(dá)與NCRT敏感性成等級相關(guān),對預(yù)測NCRT敏感性可能會有一定作用。
[Abstract]:In recent years, many scholars have started to explore how to reduce the local recurrence rate and improve the prognosis of patients with locally advanced rectal cancer. With the effect of neoadjuvant chemoradiotherapy (NCRT) in the treatment of breast cancer and the reliable effect of radiotherapy and chemotherapy after operation of rectal cancer, it is gradually applied to rectal cancer, and now has become an important part of the comprehensive treatment of local advanced rectal (LRC) cancer. I've got a lot of medical centers. The NCCN guidelines and the Chinese Code for Diagnosis and Treatment of Colorectal Cancer have also made it clear that NCRT is recommended for the c II-c stage III rectal cancer within 12 cm from the anus. However, the impact of NCRT on the prognosis of LRC is still controversial. The purpose of this study is as follows:1. The effect of NCRT on the treatment of c-鈪,
本文編號:2442427
[Abstract]:In recent years, many scholars have started to explore how to reduce the local recurrence rate and improve the prognosis of patients with locally advanced rectal cancer. With the effect of neoadjuvant chemoradiotherapy (NCRT) in the treatment of breast cancer and the reliable effect of radiotherapy and chemotherapy after operation of rectal cancer, it is gradually applied to rectal cancer, and now has become an important part of the comprehensive treatment of local advanced rectal (LRC) cancer. I've got a lot of medical centers. The NCCN guidelines and the Chinese Code for Diagnosis and Treatment of Colorectal Cancer have also made it clear that NCRT is recommended for the c II-c stage III rectal cancer within 12 cm from the anus. However, the impact of NCRT on the prognosis of LRC is still controversial. The purpose of this study is as follows:1. The effect of NCRT on the treatment of c-鈪,
本文編號:2442427
本文鏈接:http://sikaile.net/yixuelunwen/zlx/2442427.html
最近更新
教材專著